Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the biological effect of Tarceva (OSI-774) from an
inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who
are carriers of head and neck epidermoid carcinoma.